Valneva

Valneva is a specialty biotechnology firm established in 2013, dedicated to the research, development, and commercialization of prophylactic vaccines. The company focuses on addressing significant unmet medical needs by creating innovative solutions for infectious diseases, including products like Ixiaro. Operating within the biotechnology sector, Valneva maintains a robust R&D pipeline aimed at generating long-term shareholder value through the delivery of preventive medical options. The firm’s strategic focus remains on targeting diseases with limited or no available preventive options, ensuring a strong market position in the global health landscape.

With a workforce of 500-1,000 employees, Valneva manages operations across 5 locations to support its integrated commercial and manufacturing efforts. The organization leverages specialized expertise to advance vaccine candidates from early-stage development to full market access. Meet Valneva's team to understand the leadership and technical talent driving these complex biotechnology initiatives forward in a competitive global landscape. The team integrates scientific research with manufacturing excellence to maintain high standards in vaccine production and distribution across international markets.

Valneva reports annual revenue of $178.2M, reflecting its position as a key player in the vaccine market. The company has secured significant capital through various funding rounds, including debt and corporate investments from major entities like Pfizer and the European Investment Bank. Explore financial highlights to review detailed metrics regarding their fiscal performance, capital structure, and ongoing investment in vaccine technology. This financial foundation supports their continued efforts in developing next-generation prophylactic solutions.